Inhibition of the thioredoxin system for radiosensitization therapy of cancer.
Cancer
Radiosensitization
Radiotherapy
Reactive oxygen species
Thioredoxin system
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
20
11
2023
revised:
28
01
2024
accepted:
04
02
2024
medline:
18
3
2024
pubmed:
23
2
2024
entrez:
22
2
2024
Statut:
ppublish
Résumé
Radiotherapy (RT) stands as a cornerstone in the clinical armamentarium against various cancers due to its proven efficacy. However, the intrinsic radiation resistance exhibited by cancer cells, coupled with the adverse effects of RT on normal tissues, often compromises its therapeutic potential and leads to unwanted side effects. This comprehensive review aims to consolidate our understanding of how radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including gold nanoparticles (GNPs), gold triethylphosphine cyanide ([Au(SCN) (PEt
Identifiants
pubmed: 38387331
pii: S0223-5234(24)00098-9
doi: 10.1016/j.ejmech.2024.116218
pii:
doi:
Substances chimiques
gold cyanide
03I25JDS1H
Gold
7440-57-5
Radiation-Sensitizing Agents
0
Thioredoxins
52500-60-4
Cyanates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
116218Informations de copyright
Copyright © 2024 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.